Evidence map›Paper›PMID 42473553›Full record

ReviewInternational journal of nanomedicine2026

Targeting Lipid Metabolic Reprogramming to Overcome Immunotherapy Resistance: Systemic Nutritional Modulation and Precision Nanomedicine.

Qi Li, Jingyi Yang, Daozhen Chen, Yu Chen, Sunmin Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qi Li *Affiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Jingyi Yang *Affiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Daozhen ChenAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.
Yu ChenAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.ORCID 0000-0001-9420-1636
Sunmin JiangAffiliated Women's Hospital of Jiangnan University, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the clinical success of immune checkpoint inhibitors (ICIs), resistance driven by a metabolically hostile tumor microenvironment (TME), particularly lipid metabolic reprogramming, remains a formidable challenge. Tumors actively exploit lipid mediators, notably prostaglandin E2 (PGE2), to suppress CD8

Indexed as

ImmunotherapyLipid MetabolismNeoplasmsAnimalsDrug Resistance, NeoplasmFatty Acids, Omega-3HumansImmune Checkpoint InhibitorsMetabolic ReprogrammingNanomedicinePrecision MedicineTumor MicroenvironmentFatty Acids, Omega-3Immune Checkpoint Inhibitorsimmunotherapy resistancelipid metabolic reprogrammingmetabolic immunotherapynanotherapeuticsomega-3 fatty acids

Identifiers

PMID42473553
PMCPMC13380928

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.